Showing results (181-190 of 396) with videos related to
Sort By:
Pageof 40
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.Cancer Cell|July 7, 2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced deathM Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.Nature Medicine|August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanomaChe-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.Journal of Translational Medicine|September 30, 2024
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastomaHao Duan, Yuan Xie, Suwen Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaMelissa A Wilson, Fengmin Zhao, Sanika Khare, et al.BJU International|September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.Cancer Discovery|March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor ResistanceMiles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.Pageof 40